Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Creon Micro** is a brand name for an enteric-coated granule formulation of porcine pancreatic extract (pancreatin), containing lipase (5,000 Ph.Eur. units), amylase (3,600 Ph.Eur. units), and protease (200 Ph.Eur. units) per 100 mg dosing unit. It is designed as pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI), aiding digestion of fats, proteins, and carbohydrates in patients with conditions such as cystic fibrosis, chronic pancreatitis, pancreatic surgery, or gastrointestinal bypass. The minimicrospheres mix with food in the stomach, resist gastric acid due to enteric coating, and release enzymes in the duodenum (pH >5.5) to hydrolyze nutrients, improving absorption, reducing symptoms like steatorrhea, diarrhea, bloating, and malnutrition.[1][2][3][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Creon Micro.